ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Pluri Inc

Pluri Inc (PLUR)

6.08
0.55
( 9.95% )
Updated: 12:21:39

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
6.08
Bid
6.00
Ask
6.15
Volume
40,635
5.6088 Day's Range 6.08
3.7728 52 Week Range 8.48
Market Cap
Previous Close
5.53
Open
5.94
Last Trade
1
@
6.04
Last Trade Time
12:22:59
Financial Volume
$ 238,362
VWAP
5.8659
Average Volume (3m)
19,997
Shares Outstanding
5,470,163
Dividend Yield
-
PE Ratio
-1.59
Earnings Per Share (EPS)
-3.82
Revenue
326k
Net Profit
-20.89M

About Pluri Inc

Pluristem Therapeutics Inc is registered with the U.S. Security and Exchange Commission and incorporated in the state of Nevada. Pluristem Therapeutics Inc is primarely in the business of biological products (no diagnostic substances). For financial reporting, their fiscal year ends on June 30th. Th... Pluristem Therapeutics Inc is registered with the U.S. Security and Exchange Commission and incorporated in the state of Nevada. Pluristem Therapeutics Inc is primarely in the business of biological products (no diagnostic substances). For financial reporting, their fiscal year ends on June 30th. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Pluristem Therapeutics Inc. Pluristem Therapeutics Inc is a US-based company which acts as a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The lead indications are critical limb ischemia, recovery after surgery for femoral neck fracture, and acute radiation syndrome. The company operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Haifa, North, Isr
Founded
-
Pluri Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker PLUR. The last closing price for Pluri was $5.53. Over the last year, Pluri shares have traded in a share price range of $ 3.7728 to $ 8.48.

Pluri currently has 5,470,163 shares outstanding. The market capitalization of Pluri is $30.25 million. Pluri has a price to earnings ratio (PE ratio) of -1.59.

PLUR Latest News

Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority

The Israel Innovation Authority will fund Pluri and BIRAD's collaboration to advance MAIT Cell Therapy, led by Professor Cyrille Cohen, Head of the laboratory of tumor immunology and immunotherapy...

Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates

HAIFA, Israel, July 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote...

Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply

HAIFA, Israel, July 08, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), which transforms cells into solutions that promote...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.2325.36082474234.856.144.5669625.30527515CS
41.2926.93110647184.796.144.24321754.99709277CS
120.9518.51851851855.136.184.24199975.14209318CS
260.244.10958904115.846.724.24126515.29375502CS
521.480832.19690380944.59928.483.7728497605.73454257CS
156-1.92-24811.57843.4488592256.41808395CS
260-1.92-24811.57843.4488592256.41808395CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MVSTMicrovast Holdings Inc
$ 0.767999
(325.01%)
802.5M
NMHINatures Miracle Holding Inc
$ 0.1983
(131.39%)
961.97M
BTCTBTC Digital Ltd
$ 18.8703
(79.72%)
35.99M
KXINKaixin Holdings
$ 4.65
(59.25%)
44.02M
BTCSBTCS Inc
$ 4.15
(44.10%)
58.33M
SYRSSyros Pharmaceuticals Inc
$ 0.3701
(-86.44%)
29.4M
GCTKGlucoTrack Inc
$ 0.35
(-77.70%)
4.02M
PETWag Group Company
$ 0.1745
(-73.40%)
6.41M
GLXGGalaxy Payroll Group Ltd
$ 5.63
(-60.66%)
1.01M
VINOGaucho Group Holdings Inc
$ 2.3767
(-46.59%)
202.96k
NMHINatures Miracle Holding Inc
$ 0.1983
(131.39%)
961.97M
MVSTMicrovast Holdings Inc
$ 0.767999
(325.01%)
802.5M
AGRIAgriFORCE Growing Systems Ltd
$ 0.054
(13.92%)
234.28M
ELABElevai Labs Inc
$ 0.0196
(4.26%)
148.99M
XTIAXTI Aerospace Inc
$ 0.061915
(27.66%)
94.99M

PLUR Discussion

View Posts
FDApproved FDApproved 2 days ago
Placenta-Derived Mesenchymal Stromal-Like Cells Promote 3D-Engineered Muscle Tissue Differentiation and Vessel Network Maturation

https://onlinelibrary.wiley.com/doi/10.1002/smsc.202470045
👍️ 2
FDApproved FDApproved 2 days ago
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

https://finance.yahoo.com/news/brainstorm-cell-therapeutics-pluri-partner-110000497.html
👍️ 2
sekander sekander 6 days ago
The whole stock market's on fire with the Trump election but this piece of manure
can't push open its coffin lid.
👍️0
FDApproved FDApproved 6 days ago
Healthy Aging/Longevity Company Coming From Pluri Biotech Soon !!!

Future Spin-Offs !!!

1. Ever After Foods
2. Coffeesai
3. Human Longevity

👍️ 1
FDApproved FDApproved 1 week ago
Can a Placenta Cure Cancer ?

https://www.biu.ac.il/en/article/582414
👍️ 1
FDApproved FDApproved 2 weeks ago
Pluri, BIRAD bring tumor-fighting MAIT cells to commercial viability

https://www.bioprocessintl.com/deal-making/pluri-birad-bring-tumor-fighting-mait-cells-to-commercial-viability
👍️ 1
FDApproved FDApproved 2 weeks ago
4 Undervalued Hidden Gems With True Growth Potential

https://www.investing.com/analysis/4-undervalued-hidden-gems-with-true-growth-potential-200653457
👍️ 2
FDApproved FDApproved 2 weeks ago
New Company Presentation !!!

https://pluri-biotech.com/presentation/
👍️ 1
FDApproved FDApproved 2 weeks ago
https://www.contractpharma.com/contents/view_breaking-news/2024-10-28/pluri-and-bar-ilan-university-partner-to-advance-mait-cell-therapy-for-solid-tumors/
👍️ 1
FDApproved FDApproved 2 weeks ago
Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells

https://pubmed.ncbi.nlm.nih.gov/39037052/
👍️ 1
FDApproved FDApproved 2 weeks ago
Under this collaboration, Prof. Cohen’s novel Siglec-based Chimeric Switch Receptors (“CCR”) will be integrated into Pluri’s CAR-MAIT cell therapy platform to significantly enhance CAR-MAIT’s efficacy and tumor specificity.
👍️ 1
FDApproved FDApproved 2 weeks ago
Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority

https://pluri-biotech.com/releases/pluri-collaborates-with-bar-ilan-university-to-advance-cancer-immunotherapy-for-solid-tumors-supported-by-israel-innovation-authority/
👍️ 1
FDApproved FDApproved 3 weeks ago
Overcoming Scalability Barriers To Advance Cell Therapies in Development: CDMOs Can Be the Key to Success

https://www.bioprocessintl.com/cell-therapies/overcoming-scalability-barriers-to-advance-cell-therapies-in-development-cdmos-can-be-the-key-to-success
👍️ 1
FDApproved FDApproved 3 weeks ago
HealthTechShaping the Future of Longevity With Yaky Yanay And James “Jim” Roosevelt from Pluri : How Pluri’s Therapies Are Shaping the Future of Aging and Healthcare

https://techbullion.com/shaping-the-future-of-longevity-with-yaky-yanay-and-james-jim-roosevelt-from-pluri-how-pluris-therapies-are-shaping-the-future-of-aging-and-healthcare/
👍️ 1
FDApproved FDApproved 1 month ago
Interview with Lior Raviv, Chief Technology Officer at Pluri

https://techbullion.com/3d-cell-expansion-technology-revolutionizing-industries-interview-with-lior-raviv-chief-technology-officer-at-pluri/
👍️ 1
FDApproved FDApproved 1 month ago
Pluri.......IS ALL SET WITH NASDAQ COMPLIANCE !!!

GIDDY-UP !!!

On September 26, 2024, the Company received a letter from Nasdaq, determining that the Company has regained compliance and that the matter is now closed.

https://www.sec.gov/ix?doc=/Archives/edgar/data/1158780/000121390024083652/ea0216191-8k_pluri.htm
👍️ 2
FDApproved FDApproved 2 months ago
Imagine Being As Clueless As Scotty And Not Owning Lots Of Pluri !

Man, He Sure Is As Clueless As They Come !!!
👍️ 1
FDApproved FDApproved 2 months ago
Good Read !!!

https://www.contractpharma.com/issues/2024-09-01/view_features/cdmo-specialization/?widget=listSection
👍️ 1
Scott999 Scott999 2 months ago
Imagine being the CEO of a pos company that has blown through $420,000,000.00 and has got $320k in revenue for the year. I’m sure his $741k compensation for 2023. That’s on top of his $2.9 million compensation for 2023. Amazing that these guys aren’t in jail.

How that cdmo revenue do? Laughable just like the clowns. Where’s Zzatt boy when you need him? We got Zzientists. We got Zzientists
👍️ 1
FDApproved FDApproved 2 months ago
WOW !!!

https://podcast.jesslarsen.net/yaky-yanay/
👍️ 1
FDApproved FDApproved 2 months ago
Nice....Pluri Biotech- United States Patent For Non-Diabetic CLI & IC Patients
Which Is 20 to 40 % of ALL CLI Patients !!!

Note: The Patent Also Has A Digital App For Patients & Providers !!! Awesome !!!

https://patentscope.wipo.int/search/en/detail.jsf?docId=US438195758&_cid=P11-M0V2TK-99057-1
👍️ 1
FDApproved FDApproved 2 months ago
September Company Presentation:

https://pluri-biotech.com/presentation/
👍️ 1
FDApproved FDApproved 2 months ago
The Future of Cell-Based Products with Yaky Yanay, CEO of Pluri

👍️ 1
FDApproved FDApproved 3 months ago
August 27th

https://industrializingcultivatedmeats.com/expert-speakers/
👍️ 1
FDApproved FDApproved 3 months ago
Believer Meats Study is “First” Demonstration of Cost-Efficient Manufacturing of Cultivated Meat

https://cultivated-x.com/meat/study-continuous-manufacturing-cultivated-meat-significantly-reduce-costs/
👍️ 1
FDApproved FDApproved 3 months ago
Yaky Yanay, Pluri President & CEO will be presenting the Pluri story at 10.30am ET virtually on August 20, 2024.

Register To View Webcast

https://www.webcaster4.com/Webcast/Page/3062/51171
👍️ 1
FDApproved FDApproved 3 months ago
Stirring the pot: Bioreactor breakthroughs

https://www.thecellbase.com/news/stirring-the-pot-bioreactor-breakthroughs
👍️ 1
FDApproved FDApproved 3 months ago
New Tutes !!!

August 14th-UBS-- 10,167 Shares
August 15th-Jane Street-- 8,396 Share
👍️ 1
FDApproved FDApproved 3 months ago
Coffee Without Beans !!!

https://vegconomist.com/plant-cell-cultivation/companies-making-plants-cells/
👍️ 1
FDApproved FDApproved 3 months ago
Food Business News

https://www.foodbusinessnews.net/articles/26608-ever-after-foods-receives-10-million-investment
👍️ 1
FDApproved FDApproved 3 months ago
Nice !!!

https://industrializingcultivatedmeats.com/speaker/barak-zohar/
👍️ 1
FDApproved FDApproved 3 months ago
WOW !!!

https://ccr.cancer.gov/news/milestones-2024/an-unexpected-cancer-killer
👍️ 1
FDApproved FDApproved 3 months ago
Abstract: Placental-derived stromal-like cells (PLX-PAD) have been shown to facilitate muscle tissue recovery after injury and stimulate angiogenesis.

https://onlinelibrary.wiley.com/doi/full/10.1002/smsc.202400228
👍️ 1
FDApproved FDApproved 3 months ago
Kadimastem taps Pluri to produce therapeutic cells for ALS and diabetes

https://www.bioprocessintl.com/deal-making/kadimastem-taps-pluri-to-produce-therapeutic-cells-for-als-and-diabetes
👍️ 1
FDApproved FDApproved 4 months ago
Pluri’s CDMO arm takes on ALS and diabetes in cell therapy deal

https://www.biopharma-reporter.com/Article/2024/07/23/Pluri-CDMO-lands-ALS-and-diabetes-cell-therapy-deal?int_campaign=Related-News&int_campaign_type=Right_column
👍️ 1
FDApproved FDApproved 4 months ago
Pluri’s CDMO to Manufacture Kadimastem’s Cell Therapy Candidates

https://www.contractpharma.com/contents/view_breaking-news/2024-07-18/pluris-cdmo-to-manufacture-kadimastems-cell-therapy-candidates/
👍️ 1
FDApproved FDApproved 4 months ago
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates

https://pluri-biotech.com/releases/pluris-cdmo-selected-to-manufacture-kadimastems-novel-cell-therapy-product-candidates/
👍️ 1
FDApproved FDApproved 4 months ago
“By combining advanced cell expansion technology with the unique attributes of MAIT cells, Pluri is on the brink of delivering off-the-shelf solutions with unmatched consistency,” said Dr. Richard L. Kendall.

Dr. Kendall, Ph.D, is Chief Science Officer of Catena Bio, a company whose technology enables them to synthesize novel biomolecules in any structure, combination, or orientation. Previously, Dr. Kendall was the President and CEO of ImmPACT BIO, a cell therapy company developing engineered T cells for the treatment of cancer. Notably, Dr. Kendall also held significant positions at leading biopharmaceutical companies, serving as Vice President of Research at Kite Pharma, where he was responsible for the company’s research pipeline and development of CAR-T technologies, as well as Executive Director and Head of Oncology Research at Amgen.

https://drug-dev.com/pluri-launches-novel-immunotherapy-platform-for-solid-tumor-treatment/
👍️ 2
FDApproved FDApproved 4 months ago
If Pluri's CAR-Mait Cells Are Able To Treat Solid Tumors? It Will Become One Of The Most Important Advances In The History of Oncology !!!

👍️ 2
FDApproved FDApproved 4 months ago
Off the Shelf Platform: Efrat Kaduri from Pluri Inc. In a Riveting Conversation with PharmaShots

https://www.pharmashots.com/18344/off-the-shelf-platform-efrat-kaduri-from-pluri-inc-in-a-riveting-conversation-with-pharmashots
👍️ 2
FDApproved FDApproved 4 months ago
July Company Presentation:

https://pluri-biotech.com/wp-content/uploads/2024/07/Pluri-PPT-investor_Q2_July_2024-final.pdf
👍️ 2
FDApproved FDApproved 4 months ago
https://pluri-biotech.com/releases/pluri-announces-e1-million-proof-of-concept-agreement-to-enhance-global-sustainable-vegetable-supply/
👍️ 2
FDApproved FDApproved 4 months ago
Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply

https://www.streetinsider.com/Globe+Newswire/Pluri+Announces+%E2%82%AC1+Million+Proof+of+Concept+Agreement+to+Enhance+Global+Sustainable+Vegetable+Supply/23438713.html
👍️ 2
Monksdream Monksdream 4 months ago
PLUR under $10
👍️0
FDApproved FDApproved 5 months ago
"Don’t write off cultivated meat just yet, says Ever After Foods: ‘We’re not offering incremental improvements but something truly disruptive."

https://agfundernews.com/dont-write-off-cultivated-meat-just-yet-says-ever-after-foods-were-not-offering-incremental-improvements-but-something-truly-disruptive
👍️ 1
FDApproved FDApproved 5 months ago
WOW !!!

https://agfundernews.com/dont-write-off-cultivated-meat-just-yet-says-ever-after-foods-were-not-offering-incremental-improvements-but-something-truly-disruptive
👍️ 1
FDApproved FDApproved 5 months ago
Dr. Michal Sheleg on a Novel Immunotherapy Platform for Solid Tumor Treatment

https://docwirenews.com/post/dr-michal-sheleg-on-a-novel-immunotherapy-platform-for-solid-tumor-treatment
👍️ 2
FDApproved FDApproved 5 months ago
New Immune Cell Patent !!!

IMO...PLURI BIOTECH WILL DOMINATE THE GLOBAL IMMUNE CELL EXPANSION MARKET !!!

Expanded To Many Types Of Immune Cells !!

Immune cells are one of Jurkat, T2 cells, K562 cells, Raji, U973, THP-1, HL-60, Peripheral Blood Mononuclear Cells (PBMC), polymorphonuclear cells (PMN), conventional and unconventional T cells, B cells, B cell Hybridomas, CAR-B, NKT cells, CAR-NKT, gamma-delta T (gdT), CAR-gdT, NK cells, CAR-NK, and combinations thereof. Said conventional or unconventional T-Cell immune cells are unmodified or modified T cells consisting of the group: CAR-T, CAR-MAIT, modified T cell receptor (TCR)-T, modified TCR-MAIT, TILs (Tumor Infiltrating Lymphocytes), and combinations thereof.

The method according to claim 18, further comprising a step of genetically modifying said population of immune cells inside said 3D bioreactor by adding to said fluid media one or more gene modifying agents capable of genetically modifying said population of immune cells suspended in said fluid media spiked into said fluid media.

https://patentscope.wipo.int/search/en/detail.jsf?docId=US431346161&_cid=P12-LXQ3ZQ-63878-1
👍️ 2
FDApproved FDApproved 5 months ago
Pluri: Biotech Play With Several Opportunities Across Different Sectors

https://seekingalpha.com/article/4699864-pluri-several-opportunities-across-different-sectors
👍️ 2
FDApproved FDApproved 5 months ago
Excellent !!!

https://www.greenqueen.com.hk/ever-after-foods-pluri-tnuva-cultivated-meat-costs-scalability/
👍️ 2

Your Recent History

Delayed Upgrade Clock